

Sai-Juan Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8995071/publications.pdf>

Version: 2024-02-01

105
papers

8,658
citations

101384

36
h-index

48187

88
g-index

105
all docs

105
docs citations

105
times ranked

15010
citing authors

#	ARTICLE	IF	CITATIONS
1	PLCG1 is required for AML1-ETO leukemia stem cell self-renewal. <i>Blood</i> , 2022, 139, 1080-1097.	0.6	16
2	SIRT2 regulates proliferation and chemotherapy response of MLL-ENL-driven acute myeloid leukemia. <i>Biochemical and Biophysical Research Communications</i> , 2022, 596, 36-42.	1.0	5
3	Integrated analysis of gut microbiome and host immune responses in COVID-19. <i>Frontiers of Medicine</i> , 2022, 16, 263-275.	1.5	35
4	Transcriptome-wide subtyping of pediatric and adult T cell acute lymphoblastic leukemia in an international study of 707 cases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2120787119.	3.3	18
5	Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic. <i>Lancet, The</i> , 2022, 399, 2011-2012.	6.3	232
6	Functional, structural, and molecular characterizations of the leukemogenic driver MEF2D-HNRNPUL1 fusion. <i>Blood</i> , 2022, 140, 1390-1407.	0.6	10
7	Recurrent noncoding somatic and germline <i>WT1</i> variants converge to disrupt MYB binding in acute promyelocytic leukemia. <i>Blood</i> , 2022, 140, 1132-1144.	0.6	7
8	Yolk sac-derived Pcd11-positive cells modulate zebrafish microglia differentiation through the NF- κ B-Tgfi ²¹ pathway. <i>Cell Death and Differentiation</i> , 2021, 28, 170-183.	5.0	9
9	A novel KMT2A-USO1 fusion gene-induced de novo secondary acute myeloid leukaemia in a patient initially diagnosed with acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2021, 192, e32-e36.	1.2	2
10	A PML/RAR α direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia. <i>Blood</i> , 2021, 137, 1503-1516.	0.6	47
11	Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	31
12	Clinical significance of CD34 ⁺ CD117 ^{dim} /CD34 ⁺ CD117 ^{bri} myeloblast-associated gene expression in t(8;21) acute myeloid leukemia. <i>Frontiers of Medicine</i> , 2021, 15, 608-620.	1.5	13
13	Activated factor X targeted stored in platelets as an effective gene therapy strategy for both hemophilia A and B. <i>Clinical and Translational Medicine</i> , 2021, 11, e375.	1.7	4
14	Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 3683-3694.	3.2	16
15	Induced lineage promiscuity undermines the efficiency of all-trans-retinoid-acid-induced differentiation of acute myeloid leukemia. <i>IScience</i> , 2021, 24, 102410.	1.9	1
16	Gata2-L359V impairs primitive and definitive hematopoiesis and blocks cell differentiation in murine chronic myelogenous leukemia model. <i>Cell Death and Disease</i> , 2021, 12, 568.	2.7	6
17	Integrating longitudinal clinical laboratory tests with targeted proteomic and transcriptomic analyses reveal the landscape of host responses in COVID-19. <i>Cell Discovery</i> , 2021, 7, 42.	3.1	23
18	DNA crosslinking and recombination-activating genes 1/2 (RAG1/2) are required for oncogenic splicing in acute lymphoblastic leukemia. <i>Cancer Communications</i> , 2021, 41, 1116-1136.	3.7	7

#	ARTICLE	IF	CITATIONS
19	Inherent hepatocytic heterogeneity determines expression and retention of edited F9 alleles post-AAV/CRISPR infusion. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2110887118.	3.3	1
20	Interferon regulatory factor 2 binding protein 2b regulates neutrophil <i>versus</i> macrophage fate during zebrafish definitive myelopoiesis. Haematologica, 2020, 105, 325-337.	1.7	9
21	Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection. Frontiers of Medicine, 2020, 14, 746-751.	1.5	57
22	Multidimensional study of the heterogeneity of leukemia cells in t(8;21) acute myelogenous leukemia identifies the subtype with poor outcome. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 20117-20126.	3.3	31
23	SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS. Blood, 2020, 135, 2271-2285.	0.6	31
24	RIG-I regulates myeloid differentiation by promoting TRIM25-mediated ISGylation. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 14395-14404.	3.3	25
25	Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma. Cancer Cell, 2020, 37, 403-419.e6.	7.7	136
26	Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9490-9496.	3.3	1,601
27	Viral and host factors related to the clinical outcome of COVID-19. Nature, 2020, 583, 437-440.	13.7	746
28	Restoration of microRNA function impairs MYC-dependent maintenance of MLL leukemia. Leukemia, 2020, 34, 2484-2488.	3.3	15
29	An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23264-23273.	3.3	27
30	MLL is required for miRNA-mediated translational repression. Cell Discovery, 2019, 5, 43.	3.1	3
31	Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial. Lancet Haematology, 2019, 6, e328-e337.	2.2	31
32	Treating leukemia: differentiation therapy for MLL AML. Cell Research, 2019, 29, 427-428.	5.7	1
33	International Collaboration to Save Children With Acute Lymphoblastic Leukemia. Journal of Global Oncology, 2019, 5, 1-2.	0.5	9
34	Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood, 2019, 133, 1630-1643.	0.6	393
35	Destabilization of AETFC through C/EBP β -mediated repression of LYL1 contributes to t(8;21) leukemic cell differentiation. Leukemia, 2019, 33, 1822-1827.	3.3	5
36	Different roles of E proteins in t(8;21) leukemia: E2-2 compromises the function of AETFC and negatively regulates leukemogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 890-899.	3.3	18

#	ARTICLE	IF	CITATIONS
37	Differential Expression of CD49f Discriminates the Independently Emerged Hematopoietic Stem Cells and Erythroid-Biased Progenitors. <i>Blood</i> , 2019, 134, 3700-3700.	0.6	3
38	Dynamic Analysis of Cytokine Profile for Cytokine Release Syndrome in Multiple Myeloma Patients after CAR-T Cell Therapy. <i>Blood</i> , 2019, 134, 5617-5617.	0.6	2
39	Identification of fusion genes and characterization of transcriptome features in T-cell acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 373-378.	3.3	104
40	Structural basis of DUX4/IGH-driven transactivation. <i>Leukemia</i> , 2018, 32, 1466-1476.	3.3	21
41	Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation. <i>Cell Research</i> , 2018, 28, 476-490.	5.7	43
42	Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E11711-E11720.	3.3	192
43	Evaluation of the activity levels of rat FVIII and human FVIII delivered by adeno-associated viral vectors both in vitro and in vivo. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 73, 47-54.	0.6	4
44	TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells. <i>Leukemia</i> , 2018, 32, 2012-2016.	3.3	37
45	RNF4 regulates zebrafish granulopoiesis through the DNMT1-EBP1± axis. <i>FASEB Journal</i> , 2018, 32, 4930-4940.	0.2	5
46	Angiogenesis Induced By Aminoacyl-tRNA Synthetase Deficiency Is Dependent on Amino Acid Response (AAR) but Not Unfolded Protein Response (UPR) Pathways. <i>Blood</i> , 2018, 132, 77-77.	0.6	1
47	B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study. <i>EBioMedicine</i> , 2017, 16, 106-114.	2.7	15
48	Conditional knockin of Dnmt3a R878H initiates acute myeloid leukemia with mTOR pathway involvement. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 5237-5242.	3.3	54
49	Caspase-3 controls AML1-ETO-driven leukemogenesis via autophagy modulation in a ULK1-dependent manner. <i>Blood</i> , 2017, 129, 2782-2792.	0.6	39
50	GATA5 SUMOylation is indispensable for zebrafish cardiac development. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 1691-1701.	1.1	13
51	Palladin is a novel microtubule-associated protein responsible for spindle orientation. <i>Scientific Reports</i> , 2017, 7, 11806.	1.6	1
52	PALLD Regulates Phagocytosis by Enabling Timely Actin Polymerization and Depolymerization. <i>Journal of Immunology</i> , 2017, 199, 1817-1826.	0.4	6
53	Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia. <i>EBioMedicine</i> , 2016, 8, 173-183.	2.7	241
54	Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia. <i>Blood</i> , 2016, 127, 233-242.	0.6	44

#	ARTICLE	IF	CITATIONS
55	The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia. <i>Blood</i> , 2016, 128, 1525-1528.	0.6	59
56	Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes. <i>Tumor Biology</i> , 2016, 37, 4633-4640.	0.8	43
57	All-trans retinoic acid and arsenic combination therapy benefits low-to-intermediate-risk patients with newly diagnosed acute promyelocytic leukaemia: a long-term follow-up based on multivariate analysis. <i>British Journal of Haematology</i> , 2015, 171, 277-280.	1.2	12
58	CCAAT/enhancer-binding protein β is required for hepatic outgrowth via the p53 pathway in zebrafish. <i>Scientific Reports</i> , 2015, 5, 15838.	1.6	11
59	Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2015, 8, 48.	6.9	9
60	Arsenic trioxide rewires mantle cell lymphoma response to Abortezomib. <i>Cancer Medicine</i> , 2015, 4, 1754-1766.	1.3	7
61	High <i>IDH1</i> expression is associated with a poor prognosis in cytogenetically normal acute myeloid leukemia. <i>International Journal of Cancer</i> , 2015, 137, 1058-1065.	2.3	39
62	Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B. <i>Frontiers of Medicine</i> , 2015, 9, 90-99.	1.5	13
63	Mutation of <i>kri1l</i> causes definitive hematopoiesis failure via PERK-dependent excessive autophagy induction. <i>Cell Research</i> , 2015, 25, 946-962.	5.7	30
64	Characterization of Somatic Mutations in Air Pollution-Related Lung Cancer. <i>EBioMedicine</i> , 2015, 2, 583-590.	2.7	71
65	DNA methyltransferase 1 functions through <i>C/ebpa</i> to maintain hematopoietic stem and progenitor cells in zebrafish. <i>Journal of Hematology and Oncology</i> , 2015, 8, 15.	6.9	40
66	Vibsanin B Preferentially Targets HSP90 α , Inhibits Interstitial Leukocyte Migration, and Ameliorates Experimental Autoimmune Encephalomyelitis. <i>Journal of Immunology</i> , 2015, 194, 4489-4497.	0.4	23
67	Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide. <i>EBioMedicine</i> , 2015, 2, 563-571.	2.7	42
68	Sumoylation of CCAAT/enhancer-binding protein β is implicated in hematopoietic stem/progenitor cell development through regulating <i>runx1</i> in zebrafish. <i>Scientific Reports</i> , 2015, 5, 9011.	1.6	16
69	GSTT1 Deletion Is Related to Polycyclic Aromatic Hydrocarbons-Induced DNA Damage and Lymphoma Progression. <i>PLoS ONE</i> , 2014, 9, e89302.	1.1	15
70	The DNA Binding Property of PML/RARA but Not the Integrity of PML Nuclear Bodies Is Indispensable for Leukemic Transformation. <i>PLoS ONE</i> , 2014, 9, e104906.	1.1	3
71	H3K36 Histone Methyltransferase <i>Setd2</i> Is Required for Murine Embryonic Stem Cell Differentiation toward Endoderm. <i>Cell Reports</i> , 2014, 8, 1989-2002.	2.9	67
72	RIG-I Modulates Src-Mediated AKT Activation to Restrain Leukemic Stemness. <i>Molecular Cell</i> , 2014, 53, 407-419.	4.5	44

#	ARTICLE	IF	CITATIONS
73	Genomic landscape of CD34 ⁺ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8589-8594.	3.3	52
74	High IDH1 Expression Is Associated with a Poor Prognosis in Cytogenetically Normal Acute Myeloid Leukemia. Blood, 2014, 124, 5314-5314.	0.6	1
75	A panoramic view of acute myeloid leukemia. Nature Genetics, 2013, 45, 586-587.	9.4	36
76	Rig-I regulates NF- κ B activity through binding to Nf- κ b1 3' UTR mRNA. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6459-6464.	3.3	62
77	Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia. Blood, 2012, 119, 2873-2882.	0.6	45
78	High Musashi-2 Expression Is an Unfavorable Prognostic Factor in Adult B-Cell Acute Lymphoblastic Leukemia.. Blood, 2012, 120, 2508-2508.	0.6	0
79	RA-inducible gene-1 induction augments STAT1 activation to inhibit leukemia cell proliferation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 1897-1902.	3.3	74
80	Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3342-3347.	3.3	380
81	E3 Ligase c-CBL Mediates Ubiquitination-Proteasomal Degradation of BCR-ABL and Therapeutic Effects against BCR-ABL Leukemia.. Blood, 2009, 114, 3257-3257.	0.6	0
82	RIG-I plays a critical role in negatively regulating granulocytic proliferation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10553-10558.	3.3	57
83	Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2076-2081.	3.3	164
84	Front-Line Therapy with Arsenic Trioxide/All-Trans-Retinoic Acid Combination and Chemotherapy Improves Cure Rates in Newly Diagnosed Patients with Acute Promyelocytic Leukemia. Blood, 2008, 112, 2970-2970.	0.6	0
85	Rig-I Activates Expression of Interferon-Stimulated Genes (ISGs) and Inhibits the Proliferation of Acute Myeloid Leukemia Cells. Blood, 2008, 112, 2846-2846.	0.6	1
86	Rig-I ^{-/-} mice develop colitis associated with downregulation of G α i2. Cell Research, 2007, 17, 858-868.	5.7	113
87	The RAR α -PLZF Oncogenic Protein Inhibits C/EBP α Function in Myeloid Cells.. Blood, 2007, 110, 1825-1825.	0.6	0
88	Gain-of-Function Mutations of GATA-2 in Acute Myeloid Transformation of Chronic Myeloid Leukemia.. Blood, 2007, 110, 1022-1022.	0.6	9
89	RIG-G as a key mediator of the antiproliferative activity of interferon-related pathways through enhancing p21 and p27 proteins. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 16448-16453.	3.3	106
90	Histone Deacetylase Inhibitor Promotes Rituximab-Induced Apoptosis in Non-Hodgkin's B-Lymphoma Cells by NF- κ B-Mediated Bcl-2/Bcl-XL Downregulation and c-Myc Degradation.. Blood, 2006, 108, 2526-2526.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Aberrant Transcriptional Regulation of the MLL Fusion Partner EEN Gene by AML1-ETO and Its Implication in Leukemogenesis.. Blood, 2006, 108, 4330-4330.	0.6	0
92	Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7653-7658.	3.3	240
93	Coordination of Intrinsic, Extrinsic and Endoplasmic Reticulum-Mediated Apoptosis by Imatinib Mesylate Combined with Arsenic Trioxide in Chronic Myeloid Leukemia.. Blood, 2005, 106, 4841-4841.	0.6	0
94	All-trans retinoic acid/As ₂ O ₃ combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 5328-5335.	3.3	564
95	Allelic loss and gain, but not genomic instability, as the major somatic mutation in primary hepatocellular carcinoma. Genes Chromosomes and Cancer, 2001, 31, 221-227.	1.5	64
96	Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Blood, 2000, 96, 1496-1504.	0.6	209
97	Cellular and molecular mechanism of arsenic trioxide in the treatment of hematopoietic malignancies. , 1999, 5, 82-88.		0
98	Application of radiation hybrid in gene mapping. Science in China Series C: Life Sciences, 1998, 41, 644-649.	1.3	1
99	Use of Arsenic Trioxide (As ₂ O ₃) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients. Blood, 1997, 89, 3354-3360.	0.6	1,316
100	Retinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia. , 1996, 15, 147-156.		48
101	Acute promyelocytic leukemia: From clinic to molecular biology. Stem Cells, 1995, 13, 22-31.	1.4	43
102	Breakpoint clusters of thePML gene in acute promyelocytic leukemia: Primary structure of the reciprocal products of thePML-RARA gene in a patient with t(15;17). Genes Chromosomes and Cancer, 1993, 6, 133-139.	1.5	54
103	RARA and PML Genes in Acute Promyelocytic Leukemia. Leukemia and Lymphoma, 1992, 8, 253-260.	0.6	26
104	Retinoic Acid and Arsenic Trioxide Treatment in Acute Promyelocytic Leukemia: A Model of Oncoprotein Targeted Therapy. , 0, , 371-392.		0
105	COVID-19 and beyond:Âa call for action andÂaudacious solidarity to all the citizens and nations,Âit is humanityâ€™s fight. F1000Research, 0, 9, 1130.	0.8	3